Last reviewed · How we verify
18F-LNC1007 Injection
At a glance
| Generic name | 18F-LNC1007 Injection |
|---|---|
| Sponsor | Yantai LNC Biotechnology Singapore PTE. LTD. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of 18F-LNC1007 Injection PET/CT (PHASE1)
- To Compare the Clinical Application of 18F-LNC1007 Injection PET/CT and 18F-FDG PET/CT
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-LNC1007 Injection CI brief — competitive landscape report
- 18F-LNC1007 Injection updates RSS · CI watch RSS
- Yantai LNC Biotechnology Singapore PTE. LTD. portfolio CI